Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Med Food ; 19(6): 528-34, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26872103

RESUMEN

The objective of our study was to investigate whether curcumin protects against reserpine-induced gastrointestinal mucosal lesions (GMLs) in rats and to explore the mechanism of curcumin's action. Sprague-Dawley rats were randomly divided into four groups: control group, reserpine-treated group, reserpine treatment group with curcumin at high dose (200 mg/kg), and reserpine treatment group with curcumin at low dose (100 mg/kg). Rats in reserpine-treated group were induced by intraperitoneally administered reserpine (0.5 mg/kg) for 28 days. TUNEL staining and hematoxylin and eosin staining were used to evaluate the apoptotic cells and morphologic changes. In addition, to explore the mechanism of curcumin in protecting GMLs, we used serum of experimental rats to assess the level of vasoactive intestinal peptide (VIP), gastrin, interleukin-6, interleukin-10, tumor necrosis factor-α and interferon-γ by ELISA and radioimmunoassay. The protein levels of NF-κB, p-IκB-α, IκB-α, Bcl-2, Bax, and cleaved-caspase-3 were examined by western blot analysis. Data were analyzed with SPSS 19.0 software package. Curcumin treatment prevented tissue damage and cell death in the reserpine-treated rats and effectively decreased inflammatory response and balanced the expression of VIP and gastrin in the reserpine-treated rats. NF-κB, p-IκB-α, Bax, and cleaved-caspase-3 were increased in the reserpine group, but the curcumin high-dose group inhibited them. Curcumin can target the IκB-α/NF-κB pathway to inhibit inflammatory response and regulate the level of VIP and gastrin in reserpine-induced GML rats.


Asunto(s)
Antihipertensivos/efectos adversos , Curcumina/administración & dosificación , Mucosa Gástrica/efectos de los fármacos , Gastrinas/genética , Enfermedades Gastrointestinales/tratamiento farmacológico , Proteínas I-kappa B/metabolismo , FN-kappa B/metabolismo , Reserpina/efectos adversos , Péptido Intestinal Vasoactivo/genética , Animales , Mucosa Gástrica/lesiones , Mucosa Gástrica/metabolismo , Gastrinas/metabolismo , Enfermedades Gastrointestinales/etiología , Enfermedades Gastrointestinales/genética , Enfermedades Gastrointestinales/metabolismo , Humanos , Proteínas I-kappa B/genética , Masculino , FN-kappa B/genética , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Péptido Intestinal Vasoactivo/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA